ClinicalTrials.gg
RecruitingNCT07176949EOMUpdated Sep 16, 2025

Early-Onset Myopia Intervention Project

An interventional study of 0.01% atropine eye drops and 0.05% atropine eye drops in Myopia and Pre-myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Recruiting at 1 site in China. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
508
Allocation
Non-randomized
Ages
3 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Planned enrollment
6th of 54
508 · median 144
Started
2025
with 4 others
No phase
13 of 54
6 open now
Primary completion
2027-06
later than 12 of 23 live
Registered
46th of 54
by date
Lead sponsor
5 of 54
Shanghai Eye Disease Prevention and Treatment Center

Among the 54 studies testing atropine in Myopia, this one is the 6th largest by planned enrollment, is one of 5 that started in 2025, is one of 13 with no phase, reaches primary completion later than 12 of the 23 other live ones, and was the 46th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

The prevalence of myopia among children has been increasing year by year, which has become a globle public health issue. Studies have shown that defocusing lenses and atroping eyedrops can control the progression of myopia, but there is little evidence of its efficacy in myopia intervention of young pre-schoolers who will face a greater risk of progression to high myopia later in life. Therefore, this study aims to evaluate the effectiveness and safety of spectacle lenses with highly aspherical lenslets (Essilor's Stellest) , as well as 0.01% and 0.05% low concentration atropine eyedrops in myopia intervention among young children aged 3-6.

03

Conditions studied

  • Myopia
  • Pre-myopia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 3-6 years, gender unrestricted;
  • Bilateral cycloplegic spherical equivalent (SE) ≤ +0.75 D, astigmatism ≤-2.5 D, anisometropia ≤2.5 D;
  • Best corrected visual acuity: ≥0.5 for ages 3-5, ≥0.7 for age 6;
  • Accept regular follow-up, written from guardians, verbal informed consent from children;
  • Possess normal thinking and language communication skills, and can actively cooperate to wear spectacles as required.

Exclusion criteria

Exclusion Criteria:

  • Existence of strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, cataract and history of eye surgery;
  • Any ocular or systemic disease that may affect vision and refractive development (e.g., Keratoconus, Marfan syndrome, retinopathy of prematurity, etc.);
  • Current or previous use of other treatments for myopia intervention, such as pharmacological (atropine) and optical (orthokeratology lenses or DIMS spectacle lenses) approaches, interrupt use for at least 4 weeks;
  • Allergy or to cycloplegic drugs;
  • Epilepsy or other mental disorders unable to expressing consent;
  • Other conditions deemed unsuitable for participation by the researcher.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
508 participants (estimated)

Study arms

  • No intervention
    No Intervention

    No intervention for myopia control

  • Experimental
    Spectacle Lenses with Highly Aspherical Lenslets

    Wearing spectacle lenses with highly aspherical lenslets for myopia control

    Device: Spectacle lenses with highly aspherical lenslets

  • Experimental
    0.01% Atropine

    Nightly use of 0.01% atropine eyedrops for myopia control

    Drug: 0.01% atropine eye drops

  • Experimental
    0.05% Atropine

    Nightly use of 0.05% atropine eyedrops for myopia control

    Drug: 0.05% atropine eye drops

Interventions

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will use 0.01% atropine eyedrops nightly for myopia control.

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will use 0.05% atropine eyedrops nightly for myopia control.

  • DeviceSpectacle lenses with highly aspherical lenslets

    These are a special type of eyeglass lenses designed primarily to slow down the progression of myopia (nearsightedness) in children. The center of the lens provides a clear correction for distance vision, just like regular glasses. The surrounding area contains hundreds of tiny, invisible, and highly aspherical (complex curved) microlenses. These microlenses create a special optical effect. While the child looks straight ahead clearly, peripheral light rays are focused in front of the retina. This is called "myopic defocus." Research suggests that this myopic defocus signal helps to control the excessive elongation of the eyeball, which is the main cause of myopia getting worse.

06

What researchers measure

Primary outcomes

  1. Changes in cycloplegic spherical equivalence

    Measured by an auto-refractometer

    Time frame: 2 year

Secondary outcomes

  1. Changes in axial length

    Measured by an IOL-Master

    Time frame: 2 years

  2. Proportion of subjects with non-rapid myopia progression

    Rapid myopia progression is defined as: spherical equivalence increase (become less positive or more negative refractive error) of any eye ≥ 0.5 D in half a year.

    Time frame: 2 years

  3. The duration of non-rapid myopia progression

    Rapid myopia progression is defined as: spherical equivalence increase (become less positive or more negative refractive error) of any eye ≥ 0.5 D in half a year.

    Time frame: 2 years

Other outcomes

  1. Changes in choroid/retina thickness

    Measured by SS-OCT

    Time frame: 2 years

  2. Changes in BCVA

    Best corrected visual acuity

    Time frame: 2 years

  3. Changes in IOP

    Intraocular pressure

    Time frame: 2 years

  4. Changes in AMP

    Amplitude of Accommodation

    Time frame: 2 years

  5. Changes in Stereopsis

    Using Titmus Fly Test

    Time frame: 2 years

  6. Changes in TBUT

    Tear Film Break-Up Time

    Time frame: 2 years

  7. Changes in anterior segment parameters

    Measured by Pentacam

    Time frame: 2 years

  8. Changes in Hemodynamic Parameters of the Ocular Fundus

    Measured by SS-OCTA

    Time frame: 2 years

  9. Compliance indicators

    Daily wearing duration, wearing habits and patterns, frequency of eye drops use.

    Time frame: 2 years

  10. Side Effects and Adverse Events

    Incidence of glare, diplopia, blurred vision, photophobia, etc.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 24 months is close to that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 16, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
May 31, 2028
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07176949
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Jun 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Sep 16, 2025

Study contacts

Xiangui He, Prof
Contact
xianhezi@163.com
+86 15000755422

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion